Outlook Therapeutics (OTLK) Interest Coverage Ratio (2015 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Interest Coverage Ratio of 283.68 for Q1 2026, up 6.86% year-over-year from 265.47 in Q1 2025, and down 3027.19% quarter-over-quarter from 9.07 in Q4 2025.
Outlook Therapeutics (OTLK) Interest Coverage Ratio (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Interest Coverage Ratio for 12 consecutive years, with 283.68 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 6.86% year-over-year to 283.68; the TTM figure through Mar 2026 stood at 1225.03 (down 911.14% YoY), while the FY2025 annual figure was 0.46, up 11.04% from the prior year.
- Interest Coverage Ratio eased to 283.68 in Q1 2026 per OTLK's latest filing, from 9.07 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 195533.77 in Q3 2024 and bottomed at 304.56 in Q1 2025.
- Historically, Interest Coverage Ratio has averaged 11419.96 across 5 years, with a median of 17.28 in 2023.
- On a YoY basis, Interest Coverage Ratio climbed as much as 1603363.92% in 2024 and fell as far as 1890.13% in 2024.
- Outlook Therapeutics' Interest Coverage Ratio stood at 7.56 in 2022, then tumbled by 343.41% to 33.52 in 2023, then slumped by 670.21% to 258.21 in 2024, then jumped by 96.49% to 9.07 in 2025, then sank by 3027.19% to 283.68 in 2026.
- Business Quant data shows OTLK's Interest Coverage Ratio at 283.68 in Q1 2026, 9.07 in Q4 2025, and 223.95 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 1.42 |
| 10 | Outlook Therapeutics | 88.38 Mn | 77.14 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -283.68 |
| Dec 31, 2025 | -9.07 |
| Sep 30, 2025 | -223.95 |
| Jun 30, 2025 | -188.20 |
| Mar 31, 2025 | -304.56 |
| Dec 31, 2024 | -258.21 |
| Sep 30, 2024 | 195,533.77 |
| Jun 30, 2024 | -30.72 |
| Mar 31, 2024 | -39.87 |
| Dec 31, 2023 | -33.52 |
| Sep 30, 2023 | 12.19 |
| Jun 30, 2023 | -17.28 |
| Mar 31, 2023 | -2.00 |
| Dec 31, 2022 | -7.56 |
| Sep 30, 2022 | -0.14 |
| Jun 30, 2022 | -6.15 |
| Mar 31, 2022 | -1.78 |
| Dec 31, 2021 | -38.15 |
| Sep 30, 2021 | -1,166.18 |
| Jun 30, 2021 | -5,035.10 |